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Early diagnosis and dietary treatment do not prevent long-term complications, which mostly affect the central nervous system in
classical galactosemia patients. The clinical outcome of patients is highly variable, and there is an urgent need for prognostic bio-
markers. The aim of this study was first to increase knowledge on the natural history of classical galactosemia by studying a cohort
of patients with varying geno- and phenotypes and second to study the association between clinical outcomes and two possible
prognostic biomarkers. In addition, the association between abnormalities on brain MRI and clinical outcomes was investigated.
Classical galactosemia patients visiting the galactosemia expertise outpatient clinic of the Amsterdam University Medical Centre
were evaluated according to the International Classical Galactosemia guideline with the addition of an examination by a neurolo-
gist, serum immunoglobulin G N-glycan profiling and a brain MRI. The biomarkers of interest were galactose-1-phosphate levels
and N-glycan profiles, and the clinical outcomes studied were intellectual outcome and the presence or absence of movement disor-
ders and/or primary ovarian insufficiency. Data of 56 classical galactosemia patients are reported. The intellectual outcome ranged
from 45 to 103 (mean 77 6 14) and was <85 in 62%. Movement disorders were found in 17 (47%) of the 36 tested patients. In
females aged 12 years and older, primary ovarian insufficiency was diagnosed in 12 (71%) of the 17 patients. Significant differen-
ces in N-glycan peaks were found between controls and patients. However, no significant differences in either N-glycans or galact-
ose-1-phosphate levels were found between patients with a poor (intellectual outcome< 85) and normal intellectual outcome (intel-
lectual outcome85), and with or without movement disorders or primary ovarian insufficiency. The variant patients detected by
newborn screening, with previously unknown geno- and phenotypes and currently no long-term complications, demonstrated sig-
nificantly lower galactose-1-phospate levels than classical patients (P< 0.0005). Qualitative analysis of the MRI’s demonstrated
brain abnormalities in 18 of the 21 patients, more severely in patients with a lower intellectual outcome and/or with movement dis-
orders. This study demonstrates a large variability in clinical outcome, which varies from a below average intelligence, movement
disorders and in females primary ovarian insufficiency to a normal clinical outcome. In our cohort of classical galactosemia
patients, galactose-1-phosphate levels and N-glycan variations were not associated with clinical outcomes, but galactose-1-phos-
phate levels did differentiate between classical and variant patients detected by newborn screening. The correlation between brain
abnormalities and clinical outcome should be further investigated by quantitative analysis of the MR images. The variability in
clinical outcome necessitates individual and standardized evaluation of all classical galactosemia patients.
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Introduction
Classical galactosemia (CG, OMIM 230400) is one of
the more frequent inborn errors of metabolism caused by
a severe deficiency of the enzyme galactose-1-phosphate
uridylyltransferase (GALT, EC 2.7.7.12). In newborns
with CG, the ingestion of galactose causes life-threatening
illness. In the Netherlands, CG was implemented in the
newborn screening (NBS) programme in 2007. Hereafter,
31 patients have been identified: 25 patients with a clas-
sical phenotype and 6 patients with previously unreported
genotypes and phenotypes. Based on these findings, the
incidence of CG is estimated to be 1:52 800 in the
Netherlands (Welling et al., 2017b). Despite an early
diagnosis by NBS and treatment with a galactose-
restricted diet, patients are at risk to develop long-term
complications of the central nervous system, such as
abnormalities in motor and speech development, cognitive
impairment and movement disorders (MDs) and ovarian
insufficiency in females (Bosch, 2006; Hughes et al.,
2009; Waisbren et al., 2012; Coss et al., 2013; Rubio-
Gozalbo et al., 2019). There is a broad spectrum of clin-
ical manifestations ranging from fully normal to severely
impaired, even within families with identical mutations
(Fridovich-Keil and Walter, 2008; Hughes et al., 2009).
Unfortunately, at this time, the clinical outcome of indi-
vidual patients cannot be predicted because prognostic
biomarkers are lacking. This is a severe burden on
parents and patients and hampers the development of
new therapeutic options.
The pathophysiology of long-term complications is
poorly understood. The endogenous production of signifi-
cant amounts of galactose causes a persistent elevation of
harmful metabolites, such as galactose-1-phosphate (Gal-
1-P), which is considered a major factor (Berry et al.,
1995; Holton, 1995; Fridovich-Keil and Walter, 2008).
Gal-1-P has also been demonstrated to affect galactosyla-
tion (Lai et al., 2003), and N-glycan abnormalities are
reported in CG patients (Fridovich-Keil and Walter,
2008; Coman et al., 2010; Coss et al., 2012).
Remarkably, galactosylation abnormalities were seen both
after galactose intoxication and galactose over restriction
and improvement in galactosylation patterns after moder-
ate dietary galactose relaxation could indicate that dysre-
gulated glycosylation pathways are modifiable (Coman
et al., 2010; Coss et al., 2012; Knerr et al., 2015). We
hypothesize that individual differences in the extent of
galactose intoxication and galactosylation abnormalities
may contribute to the variability of the clinical outcome
spectrum observed in CG patients. Previous studies sug-
gested two possible predictors of clinical outcome. First,
an association between Gal-1-P levels and long-term out-
come in general and verbal dyspraxia in particular has
been found (Robertson et al., 2000; Webb et al., 2003;
Yuzyuk et al., 2018). Second, differences in glycosylation
patterns of immunoglobulin G (IgG) N-glycans were
found between patients and controls (Coman et al.,
2010; Coss et al., 2014; Maratha et al., 2016;
Stockmann et al., 2016) linked to specific glycan synthe-
sis gene abnormalities with a proposed correlation with
intellectual outcome (IQ) (Maratha et al., 2016). Also,
abnormal IgG N-glycosylation, as well as both inflamma-
tory and glycosylation gene expression in CG patients,
has been correlated with fertility endocrine markers in fe-
male CG patients with ovarian insufficiency (Colhoun
et al., 2018a).
The aim of this study was first to gain knowledge on
the natural history of CG by performing deep phenotyp-
ing in a relatively large cohort of patients, who are
assessed according to the international guideline (Welling
et al., 2017a) and second to study the association be-
tween two possible predictors of clinical outcome, Gal-1-
P levels and IgG N-glycan abnormalities, and long-term
complications. The effect of genotype and an early initi-
ation of treatment were also investigated, as well as the
association between abnormalities on MRI and clinical
outcome.
Materials and methods
Study design and recruitment
In this cohort study, clinical data were retrieved from the
medical records of CG patients who visited the multidis-
ciplinary galactosemia outpatient clinic in the Amsterdam
University Medical Centre (Amsterdam UMC) or who are
treated in other metabolic centres and participated in re-
search in the Amsterdam UMC. All included patients
consented to the use of their data for research purposes.
Data on intellectual and neurological functioning were
collected prospectively based on a predetermined standar-
dized assessment. Serum samples, stored in the
Amsterdam UMC Galactosemia Biobank after informed
consent of patients and/or parents, were used to measure
IgG N-glycans. The MRI was performed for research
purposes, and informed consent was obtained from all
included patients. The use of the serum samples and the
MRI study was approved by the local institutional review
board, and a waiver was given for the data collection.
Data storage
All data were stored in an electronic clinical report form
in Castor EDC, a good clinical practice compliant data
management system (Castor Electronic Data Capture, The
Netherlands, 2018).
Inclusion and exclusion criteria
Patients with an erythrocyte GALT activity <15% of the
reference mean (Shin-Bühring et al., 1976) and/or two
known pathogenic variations in the GALT gene were eli-
gible for participation in this study (Welling et al.,
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2017a). Patients with a second genetic diagnosis influenc-
ing clinical outcome were excluded.
Patient groups
For analyses, patients were divided into three groups:
i. Classical phenotypes: patients with two pathogenic
GALT gene mutations with an erythrocyte GALT en-
zyme activity below the limit of quantitation of the en-
zyme assay (<3.3%; <1.1 lmol/h.g Hb). Patients with a
classical phenotype, hereafter classical patients, can be
divided into screened patients [detected after NBS or
family screening (FS) because of an older sibling with
CG with dietary treatment started immediately after
birth] and non-screened patients (diagnosed before the
implementation of NBS, after a clinical presentation
with CG-related symptoms).
ii. Variant patients: patients detected since the introduction
of NBS in 2007 (Welling et al., 2017b). These patients
with previously unknown genotypes and phenotypes
were asymptomatic at the time of diagnosis and have re-
sidual GALT enzyme activities up to 10% in erythro-
cytes and erythrocyte Gal-1-P levels below the detection
limit (<0.05 lmol/g Hb) under treatment.
iii. Homozygous p. Ser135Leu patients: patients with
GALT deficiency in erythrocytes but residual GALT en-
zyme activity in other tissues that may improve clinical
outcome (Lai et al., 1996).
Clinical outcome measures
Patients were assessed according to the International CG
guideline (Welling et al., 2017a). In patients who received
a standardized age-specific intelligence test, the IQ was
used as derivative of intelligence (Welsink-Karssies et al.,
2019). The used intelligence tests were the Bayley Scales
of Infant and Toddler Development, the Wechsler
Preschool and Primary Scale of Intelligence, the Wechsler
Intelligence Scale for Children and the Wechsler Adult
Intelligence Scale. A poor IQ was defined as an IQ of
<85, and a normal IQ was defined as an IQ of 85.
Adult patients of whom no IQ was available and who
were unable to live independently due to cognitive im-
pairment were considered to have a poor IQ.
The neurological examination to assess the presence or
absence of MDs and standardized screening for tremors
(Fahn–Tolosa–Marin Clinical Rating Scale for Tremor,
scores ranging from 0 to 84) (Fahn et al., 1993) and dys-
tonia (Fahn–Marsden Rating Scale, scores ranging from 0
to 120) (Burke et al., 1985) were performed by one
(paediatric) neurologist (M.E.) and documented for all
patients. Since the rating scales are not validated in chil-
dren, scores of paediatric patients <12 years were not
reported in this article.
Data on speech development and the development of
gross and fine motor skills reported by the treating phys-
ician were retrieved from the medical records.
Information on the presence or absence of primary ovar-
ian insufficiency (POI) was retrieved from the medical
records of female patients.
Gal-1-P measurement in
erythrocytes
Before studying the association between Gal-1-P and clin-
ical outcomes, we evaluated the stability of erythrocyte
Gal-1-P (hereafter Gal-1-P) in our cohort of classical
patients. We found relatively stable Gal-1-P levels from
the age of 12 months (Supplementary Fig. 1), and there-
fore, measurements performed before the age of
12 months were excluded. The most recent Gal-1-P levels
reported in this article were measured by gas chromatog-
raphy–mass spectrometry and were <0.82 lmol/g Hb in
diet adherent patients. To evaluate Gal-1-P as a prognos-
tic biomarker, only dietary adherent patients were
included. Considering that the most recent Gal-1-P levels
of the classical patients were within a narrow range, life-
time Gal-1-P was also evaluated in this subgroup.
The method to measure Gal-1-P changed from spectro-
photometry (Gitzelmann, 1969) to gas chromatography–
mass spectrometry in September 2016; therefore, lifetime
Gal-1-P was defined as the mean of all Gal-1-P levels
measured between 12 months of age until September
2016. Patients with a minimum of five measurements
were included in the analysis. The Gal-1-P levels meas-
ured by spectrophotometry were <0.58 lmol/g Hb in diet
adherent patients.
IgG N-glycan measurement
Analysis of serum IgG N-glycans was performed by the
National Institute for Bioprocessing Research and
Training (Dublin, Ireland) using automated glycan prep-
aration method linked to ultra-performance liquid chro-
matography as previously described (Colhoun et al.,
2018b). The percentage areas of 28 high-resolution IgG
N-glycan peaks (GPs) were quantified in patients and
healthy controls (Stockmann et al., 2016). Based on pre-
vious research, main glycans were assigned and N-glycan
features were calculated including agalactosylated (G0),
monogalactosylated (G1) and digalactosylated (G2) struc-
tures, resulting G ratios G0/G1, G0/G2 as well as core
fucosylated bisected neutral glycans, afucosylated bisected
neutral glycans and total bisected glycans (Pucic et al.,
2011; Stockmann et al., 2013; Maratha et al., 2016).
The results of the adult CG patients were compared with
the 79 adult control samples, previously reported by
Maratha et al. (2016), and the results of the paediatric
CG patients in our cohort were compared with nine
paediatric control samples, previously reported by Coss
et al. (2014).
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MRI protocol
An open-bore 3.0-T MRI scanner (Tesla Philips Ingenia
scanner) with a 32-channel head coil was used to per-
form MRI of the brain. The MRI protocol included
three-dimensional T1-weighted and fluid-attenuated inver-
sion recovery sequences with isotropic voxels.
Image analysis
All brain MR images were scored by one neuro-radiolo-
gist (S.D.R.) blinded for the clinical outcome of patients.
The MR images were evaluated for focal white matter
abnormalities and abnormalities of the basal ganglia,
thalamus and cortex. The Fazekas scale was used to
quantify white matter abnormalities. Cerebellar atrophy
was assessed in the cerebellum and vermis. Cerebral atro-
phy was scored with the use of the global cortical atro-
phy (GCA) scale. White matter abnormalities and
atrophy were scored if the MR images deviated from the
existing age-based standards.
Statistical analysis
SPSS version 25 (SPSS Inc. Chicago, IL, USA) was used
to perform all statistical analyses. Median and ranges
were presented since data followed a non-normal distri-
bution. Descriptive statistics of patients and MR images
were reported. To determine if there were statistically sig-
nificant differences in continuous variables and propor-
tions between two groups, the Mann–Whitney U-test and
chi-square tests (or Fisher’s exact test) were used, respect-
ively. Considering the differences between the N-glycans
profiles of children and adults (Pucic et al., 2012), both
groups were analysed separately. The Spearman’s rank
coefficient test was used to test for associations, and in
case of a significant association, linear regression or logis-
tic regression was used where appropriate to test for cor-
relations. P-values <0.05 were considered statistically
significant. If multiple tests were carried out regarding a
single hypothesis, the results were corrected using the
Bonferroni–Holm method.
Data availability
The data that support the findings of this study are avail-
able upon reasonable request from the corresponding
author.
Results
In total, 70 out of 77 CG patients visiting the
Amsterdam UMC consented to the use of their clinical
data. Four patients were excluded because of a second
diagnosis influencing clinical outcome, and 10 patients
were excluded because of missing data. Demographics
and clinical outcome data of 56 patients are presented in
Table 1 on an individual level and in Table 2 on a group
level.
Previously unreported mutations detected since the im-
plementation of NBS (Welling et al., 2017b) were found
in 7 of the 55 patients, and the homozygous p.
Ser135Leu mutation was found in 2 of the 55 patients
(Table 1). In 9 of the 54 patients, erythrocyte GALT en-
zyme activity was above the limit of quantitation of the
enzyme assay (>3.3%; >1.1 lmol/h.g Hb) and ranged
from 3.6% to 9.3%.
Diagnosis and dietary treatment
Data on diagnosis were available in 50 patients. Twenty-
five patients were diagnosed in the first six weeks of life
because of CG-related symptoms, 12 patients were diag-
nosed after NBS and 10 patients were diagnosed after
family screening. In 9 of the 10 family screening diag-
nosed patients, no CG-related symptoms were reported in
the newborn period and data were missing in one pa-
tient. Three patients were diagnosed late (Table 1): two
homozygous p. Ser135Leu patients were diagnosed at age
7 months and 10 years because of feeding difficulties and
cataract and because of visual impairment due to cata-
ract, respectively. The third patient was diagnosed at age
9 months after a diagnostic delay, and information
regarding CG-related symptoms is missing.
In 32 of the 50 patients, of whom 7 patients were
diagnosed by NBS, CG-related symptoms were reported
at diagnosis. The most frequently reported symptoms
were jaundice (81%), elevated liver enzymes (58%), clin-
ical suspicion of sepsis (52%, positive blood culture
35%), feeding difficulties (45%), vomiting (33%) and
coagulopathy (30%). In the non-screened patients diag-
nosed because of critical illness (with the exclusion of the
three late diagnosed patients), the lactose free, galactose-
restricted diet was started at the median age of 10 days
(4–39) with the confirmation of diagnosis at a median
age of 11 days (4–46). In patients detected by NBS, the
diet was started at a median age of 7 days (5–8) with the
confirmation of diagnosis at a median age of 8 days (6–
11).
In 52 of the 56 patients, strict dietary adherence was
reported, while 4 of the 56 patients did not adhere to the
diet in the past or at the most recent visit.
Deep phenotyping: the clinical
outcome spectrum
Motor and speech development
The development of gross and fine motor skills was ab-
normal in 9 (21%) of the 43 and 5 (12%) of the 41
patients with available data, respectively. Speech and lan-
guage development was abnormal in 25 (58%) of the 43
patients, with a language delay in 11 (44%) of the 25
patients, a speech defect in 4 (16%) of the 25 patients
and a combination of both in 7 (28%) of the 25
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Table 1 Overview of included patients, demographics and clinical outcome
Pt ID Gender Group GALT_1/GALT_2 GALT
activity, %
IQ Tremor/
TRS
Dystonia/
DRS
POI BMD Z-score
 22 SD
1 M Non-screened p.Gln188Arg/400delT <3.3 – – – NA No
2 F Non-screened p.Gln188Arg/p.Lys285Asnp.Lus285Asn <3.3 77 – – No –
3 M Non-screened p.Gln188Arg/p.Ser135Trp <3.3 >85 – – NA –
4 M Non-screened / <3.3 – – – NA –
5 F Non-screened p.Ser135Trp/p.Arg51Gln <3.3 78 – – Yes Yes
6 M Non-screened p.Gln188Arg/p.Gln188Arg <3.3 – Yes/7 No/ NA –
7 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 78 – – Yes No
8 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 – Yes/ No/ Yes No
9 M Non-screened p.Gln188Arg/p.Lys127Glu <3.3 70 – – NA –
10 M Non-screened p.Gln188Arg/p.Gln188Arg <3.3 74 – – NA No
11 M Non-screened p.Gln188Arg/p.Gln188Arg <3.3 45 Yes/38 Yes/6 NA No
12d F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 81 Yes/4 No/0 Yes No
13 M Non-screened c.329-2A>C/c.329-2A>C <3.3 – Yes/ No/ NA Yes
14 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 83 – – Yes No
15 F Non-screened p.Gln188Arg/p.Ser135Trp <3.3 57 – – Yes No
16 F Non-screened p.Gln188Arg/p.Gln188Arg – 53 No/4 No/0 Yes No
17 F Non-screened c.329-2A>C/c.329-2A>C <3.3 – No/ No/ Yes No
18 F Non-screened p.Ser135Leu/p.Ser135Leu <3.3 71 No/1 No/0 No –
19 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 82 No/0 No/0 ? No
20c F Non-screened p.Gln188Arg/p.Leu195Pro <3.3 88 Yes/5 No/0 Yes No
21 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 71 – – ? No
22 M Non-screened p.Gln188Arg/p.Gln188Arg – 91 – – NA No
23 M Non-screened p.Gln188Arg/p.Lys195Pro <3.3 93 No/0 No/0 NA No
24 M Non-screened p.Gln188Arg/p.Ser135Trp <3.3 98 No/0 No/0 NA No
25 F Non-screened p.Arg205*/p.Trp316* <3.3 97 – – No Yes
26a M Non-screened p.Gln188Arg/p.Lys285Asn <3.3 76 Yes/7 No/0 NA No
27a M Non-screened p.Gln188Arg/p.Lys285Asn <3.3 86 Yes/6 No/0 NA No
28 F Non-screened p.Ser135Leu/p.Ser135Leu 3.9 61 No/0 No/0 No No
29 M Non-screened p.Gln188Arg/p.Ser135Trp 3.9 65 Yes/6 No/0 NA No
30e M Non-screened p.Gln188Arg/c.377þ 7A>C <3.3 87 No/3 No/0 NA No
31 M Non-screened p.Gln188Arg/p.Lys285Asn <3.3 49 Yes/29 Yes/4 NA No
32 M Non-screened p.Gln188Arg/p.Leu195Pro <3.3 103 Yes/8 No/0 NA No
33b F Non-screened p.Arg148Gln/p.Trp316* <3.3 88 Yes/13 No/0 ? No
34 F Non-screened p.Gln188Arg/p.Gln188Arg <3.3 46 Yes/ No/ – No
35f F Screened, FS p.Gln188Arg/p.Gln188Arg <3.3 77 Yes/4 No/0 Yes No
36 M Screened, FS p.Gln188Arg/p.Lys127Glu <3.3 61 – – NA No
37 F Screened, FS p.Gln188Arg/p.Arg148Gln <3.3 – – – No –
38f F Screened, FS p.Gln188Arg/p.Gln188Arg <3.3 71 – – Yes No
39d F Screened, FS p.Gln188Arg/p.Gln188Arg <3.3 61 Yes/34 Yes/1 Yes Yes
40c F Screened, FS p.Gln188Arg/p.Leu195Pro <3.3 52 Yes/10 Yes/2 ? –
41e* M Screened, FS p.Gln188Arg/c.377þ 7A>C <3.3 95 – – NA Yes
42b* M Screened, FS p.Arg148Gln/p.Trp316* <3.3 68 Yes/ No/ NA No
43* F Screened, NBS p.Gln188Arg/p.Leu195Pro <3.3 82 No/ No/ – –
44* F Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 64 No/ No/ – –
45* M Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 89 No/ No/ NA –
46* M Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 64 No/ No/ NA –
47* F Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 70 No/ No/ – –
48* M Screened, NBS p.Ser135Leu/p.*380Argext*50 <3.3 95 No/ No/ NA –
49* F Screened, NBS p.Gln188Arg/p.Gln188Arg <3.3 83 – – – –
50g* F Variant p.Val128lle/p.Val128lle 8.7 86 No/ No/ – –
51g* F Variant p.Val128lle/p.Val128lle 8.7 89 No/ No/ – –
52* M Variant p.Gln188Arg/p.Met219Lys 7.2 96 No/ No/ NA –
53* F Variant p.Gln188Arg/c.1-96T>G 3.6 86 No/ No/ – –
54g* M Variant p.Val128lle/p.Val128lle 9.3 91 No/ No/ NA –
55* M Variant p.Arg201His/p.Arg201His 8.9 – – – NA –
56g* F Variant p.Val128lle/p.Val128lle 6.3 – – – – –
*Age <12 years.
Pt ID: patient ID; F: female; M: male; FS: family screening; IQ: intelligence quotient; TRS: tremor rating scale; DRS: dystonia rating scale; BMD: bone mineral density; NA: not applic-
able; -: data not available; ?: data unclear; a, b, c, d, e, f: sibs, patients are ordered by group and listed by decreasing age; bold: patients diagnosed late.
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patients. In three (12%) patients, the speech and language
development problems were not further specified. The fre-
quency of abnormal motor, speech and language develop-
ment did not differ between classical non-screened and
classical screened patients.
Ophthalmology
In 12 of the 49 patients, cataract was present at the most
recent ophthalmic evaluation, 11 of the 49 had cataract
in the past, which had resolved, and 26 of the 49
patients have never been diagnosed with cataract. The
most frequently reported description was stable, nuclear
cataract without visual impairment.
General intelligence
In 47 patients, IQ testing was performed. As a group, the
included patients demonstrated an overall below average
but highly variable intelligence with the IQ ranging be-
tween 45 and 103 (mean 78, 14 SD). Three adult
patients were unable to live independently due to cogni-
tive impairment. A total of 31 patients had a poor IQ,
and 19 patients had a normal IQ. There was no signifi-
cant difference in IQ between classical non-screened and
classical screened patients (Table 3).
Neurology
In 36 of the 56 patients, an examination by a (paediatric)
neurologist including a standardized screening for tremors
and dystonia was performed at the outpatient clinic visit.
Neurologic complaints were self-reported by 10 of the 36
patients (four adults) or their parents (six children) and
ranged from a poor handwriting to symptoms interfering
with activities in daily life. In 17 of the 36 (9/22 chil-
dren, 8/14 adults), the neurologic examination was ab-
normal of whom 12 patients had a subtle tremor,
1 patient had an evident tremor and 4 patients demon-
strated both an evident tremor and dystonia.
Of the 12 patients with a subtle tremor, 9 had an ac-
tion tremor, 2 had a postural and action tremor and 1 pa-
tient had a postural and intention tremor. Of the five
patients with an evident tremor, two patients had a com-
bined action and postural tremor and two patients had
an action tremor only and in one patient the nature of
the tremor was not specified.
Twenty patients aged 12 years and older underwent
standardized screening for tremors and dystonia by the
previously described rating scales (Table 1).
Neurologic comorbidity was reported in patients with
and without MDs. The most severely affected patient had
a complex MD with a dystonic tremor and spastic para-
paresis. This patient had a meningitis in the neonatal
Table 2 Patient groups and clinical outcomes
n All patients
(n 5 56)
n Classical
patients (n 5 47)
n Variant
patients (n 5 7)
n Homozygous
p.Ser135Leu
(n 5 2)
Gender 56 47
Male 26 23 3
Female 30 24 4 2
Age (years) 56 18.0 (0–48) 47 21.0 (4–48) 7 5.0 (0–7) 2 16/23
Paediatric patients (<18 years) 27 19 7 1
Adult patients (18 years) 29 28 1
GALTactivity (%) 54 45 7 2
<3.3 45 44 1
3.3 9 1 7 1
IQ 47 78 (45–103) 40 77 (45–103) 5 89 (86–96) 2 61/71
IQ < 85 29 27 2
IQ  85 18 13 5
Neurology 36 29 5 2
MDs, no 19 12 5 2
MDs, yes 17 17
TRS 20 5.5 (0–38) 18 6.0 (0–38) 2 0/1
DRS 20 0.0 (0–6) 18 0.0 (0–6) 2 0/0
Endocrinology (females 12 years) 21 19 2
Puberty induced, no 11 9 2
Puberty induced, yes 8 8
POI, no 5 3 2
POI, yes 12 12
Gal-1-P (lmol/g Hb) in erythrocytesa 50 0.35 (0.0–0.70) 43 0.37 (0.16–0.70) 7 0.0 (0–0.13) 2 0.14/0.13
Galactitol (mmol/mol creatinine) in urinea 34 120 (0–311) 25 140 (109–311) 7 10 (0.0–97) 2 69/58
Data reported in median and ranges.
aMost recent value is presented.
IQ: intelligence quotient; TRS: tremor rating scale; DRS: dystonia rating scale.
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period and suffers from epileptic seizures (tonic–clonic
and focal with impaired consciousness) treated with mul-
tiple anti-epileptic drugs. Neurological comorbidity was
reported in two other patients with an MD [epilepsy
(n¼ 1) and neonatal meningitis (n¼ 1)] and in two
patients without an MD [traumatic brain injury leading
to a skull fracture with increased intracerebral pressure
(n¼ 1) and neonatal meningitis (n¼ 1)].
In patients with an MD, the motor development was
abnormal in 42% and the speech development was ab-
normal in 75%, which is in contrast to patients without
an MD in whom motor and speech development were
abnormal in 16% and 38%, respectively.
The frequency of MDs did not differ between classical
non-screened and classical screened patients (Table 3).
Magnetic Resonance Imaging
A total of 21 CG patients (8–47 years, 9 males and 12
females) underwent MRI of the brain, and in 18 of the
21 patients, brain abnormalities were found (Table 4).
The supratentorial white matter appeared normal in 12
patients (median age 17.0 years, 8–31). In 9 of the 21
patients (median age 26.0 years, 18–47), focal deep white
matter abnormalities were found, most frequently in the
frontoparietal region, with confluent white matter abnor-
malities in 1 patient. In none of the patients, focal abnor-
malities were found in the infratentorial white matter,
basal ganglia, thalamus and cortex.
In 4 patients, no atrophy was detected, 12 patients
demonstrated both cerebral and cerebellar atrophy, 4
patients demonstrated cerebral atrophy only and 1 pa-
tient demonstrated cerebellar atrophy only. Cerebral atro-
phy varied from minimal atrophy in one region of the
brain to atrophy in multiple regions, up to a GCA score
of 2 per region. Parietal (16/17) and frontal (9/17) were
the most affected cerebral regions, and the vermis was
the most affected cerebellar region (13/17).
All patients who underwent an MRI received IQ test-
ing. The median IQ was 78 (49–98). Six of the 21
patients had a normal IQ (IQ  85). Thirteen out of 21
patients were examined by a neurologist, who diagnosed
an MD in eight patients.
The presence of white matter abnormalities was not
associated with IQ nor MDs.
Patients with a poor IQ (IQ< 85) had significantly
more cerebral atrophy (higher GCA scores) than patients
with a normal IQ (P¼ 0.011). The IQ (as continuous
measure) was associated with cerebral atrophy (the GCA
score) (P¼ 0.014). The presence of cerebellar atrophy
was significantly higher in patients with a poor IQ
(P¼ 0.014), and the IQ (as a continuous measure) was
associated with cerebellar atrophy (P¼ 0.028).
MDs were associated with GCA scores (P¼ 0.041), and
patients with MDs demonstrated significantly higher
GCA scores than patients without MDs (P¼ 0.048).
Patients with MDs did not demonstrate a higher fre-
quency of cerebellar atrophy.
Table 3 Clinical outcomes of non-screened and screened classical patients
n Classical non-screened
patients (n 5 32)
n Classical screened
patients (n 5 15)
P-value
Gender 32 15
Male 17 6 0.534
Female 15 9
Age (years) 32 24.5 (11–48) 15 10.0 (4–32) 0.002
Paediatric patients (<18 years) 9 10 0.024
Adult patients (18 years) 23 5
GALTactivity (%) 30 15
<3.3 29 15 1.000
3.3 1
IQ 26 78.0 (45–103) 14 71.0 (52–95) 0.421
IQ < 85 16 10 1.000
Q  85 10 4
Neurology 19 10
MDs, no 6 6 0.236
Ds, yes 13 4
TRS 15 6.0 (0–38) 3 10.0 (4–34) 0.311
DRS 15 0.0 (0–6) 3 1.0 (0–2) 0.104
Endocrinology (females  12 years) 14 5
Puberty induced, no 7 2 0.620
Puberty induced, yes 5 3
POI, no 2 1 1.000
POI, yes 9 3
Gal-1-P (lmol/g Hb) in erythrocytesa 28 0.36 (0.24–0.62) 15 0.40 (0.16–0.70) 0.221
Galactitol (mmol/mol creatinine) in urinea 14 128 (109–168) 11 175 (113–311) 0.204
Data reported in median and ranges.
aMost recent value is presented.
IQ: intelligence quotient; TRS: tremor rating scale; DRS: dystonia rating scale.
Bold numbers defining as statistically significant.
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The frequency of MRI abnormalities (white matter
abnormalities, cerebral and cerebellar atrophy) did not
differ between classical non-screened and classical
screened patients.
Endocrinology
Of 21 out of 30 females aged 12 years and older at the
time of data collection, data on the endocrinological out-
come were available. During the most recent visit, the
menarche had occurred in all patients. The median age at
puberty induction (n¼ 8) was 12 years (11–15 years) with
the menarche at a median age of 15 years (12–17 years),
while a spontaneous menarche (n¼ 11) occurred at a me-
dian age of 13.5 years (12–16 years). The diagnosis POI
was reported in 12 of the 17 females and is uncertain in
four. All females with POI received hormone replacement
therapy at the most recent visit. Both p. Ser135Leu
homozygous patients had a normal puberty development
and have no POI. The frequency of POI did not differ
between classical non-screened and classical screened
patients (Table 3).
Bone health
In 36 of the 56 patients, the results of a dual-energy X-
ray absorptiometry scan were available. In total, 3 of the
17 children (18%) and 2 of the 19 adults (11%) had a
bone mineral density 2 SD at the most recent dual-en-
ergy X-ray absorptiometry scan. The Z-scores of the fem-
oral neck and lumbar spine did not significantly differ
between males and females nor between children and
adults.
A history of fractures was reported in 7 of the 30
patients. In these patients, the bone mineral density was
2 SD in two patients and normal in three patients
and two patients were too young to undergo a dual-en-
ergy X-ray absorptiometry scan. All reported fractures
were preceded by a trauma.
NBS-detected variant patients
A recently identified group of patients present in this co-
hort are the seven NBS-detected variant patients
(Tables 1 and 2) of whom four are siblings. Six variant
patients have erythrocyte Gal-1-P levels below the detec-
tion limit (<0.05 lmol/g Hb) and normal urine galactitol
levels on a galactose-restricted diet, while one patient
with a residual erythrocyte GALT activity of 3.6% (just
above the limit of quantitation) demonstrated variable
Gal-1-P levels ranging from below the detection limit to
0.13 lmol/g Hb as the highest measured level and galacti-
tol levels above the normal range. The most recent Gal-
1-P and galactitol levels were significantly lower in the
variant patients when compared with the classical
patients (P< 0.0005).
In the four patients with the highest GALT enzyme
activities (8.7–9.3%) and normal metabolites on a galact-
ose-restricted diet, the diet was relaxed to a maximum
daily allowance of 1200 mg galactose (50 ml dairy prod-
uct) in three patients and 2400 mg galactose (100 ml
dairy product) in one patient. The dietary relaxation did
not increase the Gal-1-P or galactitol levels in any of
these patients.
The assessment of two variant patients was limited due
to their young age (4 and 23 months). In the assessed
patients, the development of gross and fine motor skills
was normal. The speech development was normal in all
but one patient, who suffered from persistent adenoiditis
for whom two adenoidectomies were required in the first
Table 4 Brain MRI abnormalities in patients
Pt ID Fazekas Cerebellum Vermis Cerebrala Frontala Parietala Temporala Occipitala IQ MD
2 2 þ þ 1–2 2 2 1 1 77 –
5 1 þ þ 1 1 2 0 1 78 –
7 1 6 6 1 1 1 1 0 78 –
35 1   0 0 1 0 0 77 Yes
36 0  þ 1 1 1 1 1 61 –
12 0 þ þ 0–1 1 1 0 0 81 Yes
14 1  þ 0 0 0 0 0 83 –
38 1  6 0–1 1 1 0 0 71 –
39 1 þ þ 1 1 1 1 1 61 Yes
19 0  þ 0 0 1 0 0 82 No
20 0  þ 0 0 1 0 0 88 Yes
24 0   0 0 0–1 0 0 98 No
22 1   0 0 1 0 0 91 –
23 1   0 0 0 0 0 93 No
40 0 þ þ 0 0 1 0 0 52 Yes
28 0  þ 0 0 1 0 0 61 No
31 0 6 þ 0–1 1 1 0 0 <50 Yes
42 0   0–1 1 1 0 0 68 Yes
aGCA scale (scores ranging from 0 to 3 per region).
þ: atrophy is present; : atrophy is absent; 6: minor atrophy; IQ: intelligence quotient; -: data not available; Pt ID: patient ID corresponds with Table 1. Patients are listed by
decreasing age.
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2 years of life. Currently, none of the variant patients
demonstrates long-term complications.
Homozygous p. Ser135Leu patients
In spite of a late diagnosis and late onset of a galactose-
restricted diet, both patients do not demonstrate POI or
MDs. However, both patients demonstrated a poor IQ
with an IQ well below 85. Both patients have lower Gal-
1-P and galactitol levels than classical patients (Table 1)
and at times Gal-1-P levels even below the detection limit
despite dietary incompliance in one patient.
Possible predictors of clinical
outcome
The most recent Gal-1-P level
The most recent Gal-1-P level measured by gas chroma-
tography–mass spectrometry was available in 50 patients.
There were no significant differences in Gal-1-P levels be-
tween children and adults nor between males and
females. The Gal-1-P levels between patients with a poor
and normal IQ and with and without MDs and POI
were not significantly different. Linear regression analysis
indicated that Gal-1-P was not a significant predictor for
IQ (P¼ 0.90). Logistic regression to evaluate if Gal-1-P
was able to predict POI and MDs was considered unreli-
able due to broad confidence intervals.
In the screened patient group, patients with a normal
IQ (n¼ 9) had significantly lower Gal-1-P levels than
patients with a poor IQ (n¼ 10) (P¼ 0.017). This group
includes the variant patients with higher GALT activities
in erythrocytes and significantly lower Gal-1-P levels than
the classical patients (P< 0.0005). There was a significant
negative correlation between the Gal-1-P levels and
erythrocyte GALT activity (P< 0.0005). In the screened
classical patients, there was no significant difference in
Gal-1-P levels between patients with a poor and normal
IQ.
In the screened patient group, the Gal-1-P levels be-
tween patients with and without MDs and POI demon-
strated no significant differences.
Lifetime Gal-1-P
The lifetime Gal-1-P level measured by spectrophotometry
was available in 29 patients. The average number of Gal-
1-P measurements per patient was 14 (5–59). The lifetime
Gal-1-P levels between classical patients with a poor and
normal IQ and with and without MDs and POI were not
significantly different.
To investigate whether lifetime Gal-1-P was stable from
12 months, the association with age was tested, demon-
strating a significant negative correlation between age
and lifetime Gal-1-P (P¼ 0.043). The inclusion of patients
with <5 Gal-1-P measurements did not change this
finding.
N-glycan profiles
In total, 9 of the 28 GPs were significantly different
when the samples of adult CG patients were compared
with the control samples (P 0.001). From these nine
GPs, a major trend emerges that the bisecting glycans in-
crease in CG patients (GP3, GP21 and GP26, Fig. 1).
Also, an increase in afucosylated bisected glycans was
observed when compared with controls (Table 5 and
Supplementary Fig. 2A). There were no significant differ-
ences in GPs, G ratios or IgG N-glycan features (core
fucosylation and bisected GlcNAcylation) between adult
patients with a poor and normal IQ and patients with or
without MDs or POI (data not shown).
In the paediatric patients, GP15 (containing core fuco-
sylated biantennary digalactosylated glycan FA2G2 as the
major glycan) was significantly decreased and GP21 (con-
taining bisected digalactosylated monosialylated glycan
A2BG2S1 as the major glycan) was significantly increased
when compared with the nine control samples (P 0.001,
Fig. 2, individual data shown in Supplementary Fig. 3A
and B). The core fucosylated bisected neutral glycans,
afucosylated bisected neutral glycans and total bisected
glycans were significantly higher in paediatric patients
when compared with controls (Table 6 and
Supplementary Fig. 2B). There were no significant differ-
ences in GPs or G ratios between paediatric patients with
a poor and normal IQ and with and without MDs. Both
core fucosylated bisected neutral glycans and total
bisected glycans were significantly higher in paediatric
patients with MDs (Supplementary Table 1). The exclu-
sion of the variant patients and homozygous p.
Ser135Leu patients did not change any of these results.
Discussion
The aim of this cohort study, which includes >30% of
all Dutch CG patients, was to perform deep phenotyping
and to investigate the association between long-term com-
plications and possible predictors of clinical outcome.
The results of our study reflect the broad clinical out-
come spectrum of CG with an overall below average in-
telligence and the frequent occurrence of MDs, brain
abnormalities on MRI and POI in females.
The neurological examination revealed MDs in 47% of
patients, which is comparable to the results of Kuiper
et al. (2019) but less frequent than reported by Rubio-
Agusti et al. (2013). This finding might be explained by
the fact that the latter reported on adults only, and it
confirms the lower frequency of MDs in children, which
has also been reported previously (Kuiper et al., 2019).
Interestingly, tremors were more frequently and dystonia
less frequently observed in our cohort when compared
with previous studies (Rubio-Agusti et al., 2013; Kuiper
et al., 2019). Unlike other cohorts, ataxia was not found
in our patients.
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Patients with a poor IQ and/or MDs demonstrated
more brain abnormalities on MRI than patients without
MDs and a higher IQ. The finding that the presence of
cerebellar atrophy is associated with IQ is in accordance
with previous research that suggested that the cerebellum
might be involved in cognition (Rapoport et al., 2000;
Timmann et al., 2010).
Puberty was induced in 42% of the females aged
12 years and older, and POI was diagnosed in 71%. This
frequency is lower when compared with other studies
(Waisbren et al., 2012; Coss et al., 2013), possibly be-
cause our cohort also includes two homozygous p.
Ser135Leu patients without POI.
A low bone mineral density (Z-score  2 SD) was
reported in 14% of the patients, compared with 2.3% in
the general population. This finding is in line with previ-
ous estimations (van Erven et al., 2017). We found a
higher frequency of low bone mineral density in children
Table 5 N-glycans of adult patients
CG patients (n 5 17) Controls (n 5 79) P-value Main glycansa
GPsb
GP1c 0.27 (0.23–0.39) 0.66 (0.26–1.95) <0.0005 FA1
GP3d 1.04 (0.79–1.25) 0.39 (0.22–0.57) <0.0005 A2B
GP5c 0.15 (0.13–0.21) 0.19 (0.01–0.26) 0.001 M5
GP7d 1.17 (0.58–1.44) 0.52 (0.23–0.95) <0.0005 A2[3]G1
GP15d 0.15 (0.09–0.23) 0.07 (0.00–20.25) <0.0005 FA2G2
GP18c 0.14 (0.09–0.18) 0.42 (0.22–2.75) <0.0005 FA2G1S1
GP21d 0.27 (0.15–0.34) 0.19 (0.10–11.50) <0.0005 A2BG2S1
GP24c 0.03 (0.01–0.05) 0.06 (0.03–0.36) <0.0005 ?
GP26d 0.20 (0.08–0.33) 0.11 (0.04–0.70) <0.0005 A2BG2S2
Glycan featuresa
Bn 1.57 (1.19–1.69) 0.85 (0.44–22.50) <0.0005 Afucosylated neutral glycans
Data reported in median and ranges. Only significant differences are shown.
aMain glycans were assigned and N-glycan features calculated as described in Pucic et al. (2011).
bThe percentage areas of 28 IgG N-GPs, quantified as described in Stockmann et al. (2016).
cDecreased in CG patients (when compared with controls).
dIncreased in CG patients (when compared with controls).
Bn: afucosylated bisected neutral glycans; ?: unknown.
Figure 1 IgG N-GPs adult patients and controls. The percentage areas of 28 IgG N-GPs, quantified in adult galactosemia patients and
controls as described in Stockmann et al. (2016). Data reported in median (ranges) with error bars. ‘ Significantly different GPs (P0.001), as
shown in Table 5.
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than in adults, suggesting later maturation as previously
reported in CG (Waggoner et al., 1990) and improve-
ment with age. Considering that no fragility fractures
were reported in our cohort, the clinical relevance of the
higher incidence of low bone mineral density in CG
patients remains uncertain.
Our cohort consists of classical, homozygous p.
Ser135Leu and NBS-detected variant patients. In the
largest group, the classical patients, the patients with
identical genotypes and biochemical outcomes demon-
strated highly variable clinical outcomes. The frequency
of long-term complications did not differ between
screened and non-screened classical patients. Thus, early
diagnosis and initiation of treatment does not explain the
differences in clinical outcome, which is in line with pre-
vious research (Fridovich-Keil and Walter, 2008; Hughes
Table 6 N-glycans of paediatric patients
CG patients (n 5 23) Controls (n 5 9) P-value Main glycansa
GPsb
GP15c 0.13 (0.09–0.24) 0.17 (0.14–0.21) 0.001 FA2G2
GP21d 0.23 (0.12–0.37) 0.17 (0.11–0.18) <0.0005 A2BG2S1
Glycan featuresa
FBnd 9.55 (7.40–18.80) 8.31 (5.72–10.25) 0.022 Core fucosylated bisected glycans
Bnd 1.66 (1.33–2.38) 1.25 (1.09–1.73) 0.002 Afucosylated neutral glycans
Bd 14.78 (11.35–29.49) 12.32 (9.06–13.93) 0.001 Total bisected glycans
Data reported in median and ranges. Only significant differences are shown.
aMain glycans were assigned and N-glycan features calculated as described in Pucic et al. (2011).
bThe percentage areas of 28 IgG N-GPs, quantified as described in Stockmann et al. (2016), Coss et al. (2016).
cDecreased in CG patients (when compared with controls).
dIncreased in CG patients (when compared with controls).
FBn: core fucosylated bisected neutral glycans; FBn: GP6þ 11þ 12þ 17; Bn: afucosylated bisected neutral glycans; Bn: GP3þ 8þ 14; B: total bisected glycans; B:
GP3þ 6þ 8þ 11þ 12þ 14þ 17þ 21þ 23þ 26þ 28.
Figure 2 IgG N-GPs paediatric patients and controls. The percentage areas of 28 IgG N-GPs, quantified in paediatric galactosemia
patients and controls as described in Stockmann et al. (2016). Data reported in median (ranges) with error bars. ‘ Significantly different GPs
(P0.001), as shown in Table 6. Individual data shown in Supplementary Fig. 3A and B.
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et al., 2009; Kuiper et al., 2019). The highly variable
clinical outcome spectrum of CG patients and the diver-
sity in genotypes, phenotypes and biochemistry underline
the need for predictors of clinical outcome.
In our cohort, Gal-1-P and N-glycans as possible pre-
dictors of clinical outcome were investigated. Both life-
time and the most recent Gal-1-P levels of patients with
and without long-term complications were not significant-
ly different. This seems to be in contrast to the findings
of Yuzyuk et al. (2018) who evaluated lifetime Gal-1-P.
In the screened patients in our cohort, we did find signifi-
cantly lower Gal-1-P levels in patients with a normal IQ.
However, this resulted directly from the inclusion of the
NBS-detected variant patients with a different biochemical
profile. In the cohort reported by Yuzyuk et al., the life-
time Gal-1-P levels of patients with a normal long-term
outcome were indeed lower. However, some of these
patients are comparable to the variant patients in our co-
hort with higher residual GALT activities and lower Gal-
1-P levels. In our cohort, the most recent Gal-1-P levels
were able to discriminate between classical and variant
patients, but both the lifetime and the most recent Gal-1-
P levels were not able to discriminate between classical
patients with a poor and normal clinical outcome.
Previous research reported a stabilization in Gal-1-P
within a year (Walter et al., 1999; Yuzyuk et al., 2018).
However, the evaluation of lifetime Gal-1-P in our cohort
of classical patients demonstrated a significant negative
correlation between lifetime Gal-1-P and age. This indi-
cates a more gradual but further decline in Gal-1-P after
the age of 12 months. As it is currently unclear if and
when Gal-1-P stabilizes, caution is required for its use as
prognostic biomarker.
The evaluation of N-glycan profiles demonstrated N-
glycan variations in CG patients with significant differen-
ces between patients and controls for various N-GPs. In
our cohort, adult patients showed more differentiation
between N-GPs when compared with controls than paedi-
atric patients. N-GP GP21, containing bisecting glycans,
as well as afucosylated bisected neutral glycans, was
found to be significantly higher in CG patients when
compared with controls in both paediatric and adult
patients. This observation conflicts with previous findings
(Maratha et al., 2016), where this glycan feature was
found to be decreased but does correlate with the more
recently published study (Colhoun et al., 2018a) where
MGAT3 gene expression is significantly upregulated in
CG patients. MGAT3 gene encodes b-1,4-mannosyl-
glycoprotein 4-b-N-acetylglucosaminyltransferase, which
adds bisecting GlcNAcs to N-glycans. Possible limitations
in all studies are the small sample sizes, and the patients
from these studies may have different phenotypes includ-
ing ethnicity and GALT variants. In contrast to previous
research, G ratios were not informative in our cohort of
patients (Coss et al., 2012; Coss et al., 2014).
In our cohort, both core fucosylated bisected neutral
glycans and total bisected glycans were significantly
higher in paediatric patients with MDs and there may be
link to glycan dysregulation in the central nervous sys-
tem. No other significant differences in N-glycans be-
tween patients with and without long-term complications
were found in our cohort, and it remains unclear if (on-
going) galactosylation abnormalities may be able to pre-
dict clinical outcome in CG (Coss et al., 2014; Maratha
et al., 2016; Stockmann et al., 2016). At this moment,
the clinical relevance of the (main) glycan abnormalities
found in CG patients is unclear and future research is
needed to investigate this further.
Limitations
Even though 56 patients is one of the larger reported CG
cohorts, patient numbers are small due to the rarity of
the disorder. Furthermore, missing data posed a challenge
in the statistical analyses. The use of tremor and dystonia
rating scales is hampered because of the lack of control
data and age-dependent scales, particularly in the paediat-
ric population where higher scores might represent imma-
ture movements due to incomplete brain maturation
instead of pathology.
In this study, the fluid-attenuated inversion recovery se-
quence was used to assess focal white matter abnormal-
ities on MRI. In certain areas of the brain, most notably
deep grey matter and infratentorial structures, T2-
weighted images are known to have a higher sensitivity.
Unfortunately, this sequence was not available in our
MRI protocol.
Even though plasma glycans in individuals have been
shown to be stable, a high level of variability has been
observed within populations and age-, gender-, environ-
mental- and physiological influences have been reported
(Gornik et al., 2009; Knezevic et al., 2009). Moreover,
the N-glycan profiles consist of multiple variables, which
require correction for multiple testing.
Moreover, in this study, both erythrocyte Gal-1-P and
serum IgG N-glycans were investigated as these are easy
to collect and relatively non-invasive when compared
with other tissues. The question remains whether Gal-1-P
and N-glycans in the affected tissues such as brain and
ovaries would provide different results. As Gal-1-P is
trapped into the cells due to its charged nature, the Gal-
1-P levels measured in erythrocytes may not represent the
Gal-1-P levels in the affected tissues. Also, serum IgG N-
glycans may not represent glycosylation patterns in the
affected tissues.
The elimination of possible confounders such as age
and genetic heterogeneity in the N-glycan analyses and
genetic heterogeneity in the Gal-1-P analysis reduced the
sample size even further, and therefore, definitive conclu-
sions on the prognostic value of Gal-1-P and N-glycans
cannot be drawn.
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Strengths
In this study, we included >30% of the total Dutch CG
population. The clinical assessment based on the CG
guideline enabled a standardized evaluation, and patients
with a second (genetic) diagnosis influencing clinical out-
come were excluded. A prospective study design was
used for the intelligence testing and neurological examin-
ation. Moreover, the neurological examination was per-
formed by one (paediatric) neurologist and complemented
with tremor and dystonia rating scales.
Since variant patients and p. Ser135Leu homozygous
patients differ from classical CG patients in genotypes,
biochemistry and clinical outcomes, which may influence
the results, analyses, were repeated after the exclusion of
the homozygous p. Ser135Leu and variant patients.
Future perspectives
In our cohort, we demonstrated a highly variable clinical
outcome with a frequency of long-term complications
comparable to previous studies. A long-term complication
that has yet received limited attention in the literature is
MDs. A standardized neurological evaluation is war-
ranted in all patients, but especially in children with a
delay in motor and speech development. Importantly, the
impact of the MDs on daily functioning and the possible
progressiveness of MDs with age should be investigated.
We hypothesized that the variability in clinical outcome
in CG patients is caused by differences in the extent of
galactose intoxication and galactosylation abnormalities.
However, the results indicate that Gal-1-P and N-glycans
were not able to predict clinical outcome in our cohort.
This may well be the result of limited power and under-
lines the need for international collaboration to increase
patient numbers in studies evaluating predictors of clinic-
al outcome. Importantly, age variability and stability of
Gal-1-P should be further investigated.
A remarkable group in our cohort are the variant
patients detected since the introduction of NBS with pre-
viously unknown genotypes and different clinical and bio-
chemical phenotypes. Currently, all patients with enzyme
activities <15% are treated (Welling et al., 2017a); how-
ever the question remains if the variant patients with
higher erythrocyte GALT activity (up to 10%) are indeed
patients in need of strict dietary treatment, especially
since galactose over restriction might be harmful (Knerr
et al., 2015). After the first months of life, the variant
patients demonstrated mostly normal Gal-1-P levels even
after galactose allowance in some. To determine the opti-
mal treatment of this group, which constitutes 14% of
patients detected by NBS in the Netherlands (Welling
et al., 2017b), further studies of galactose tolerance are
warranted.
To develop prognostic biomarkers, improving our
understanding of galactose metabolism and the
underlying mechanism of long-term complications is cru-
cial. Future studies focusing on galactose metabolism at
cell level preferably in the affected tissues and whole
body metabolism could provide more insight. In addition,
more research into the brain abnormalities on MRI and
the association with clinical outcome may be of value.
Visible lesions on MRI are relatively scarce in CG
patients and may not satisfyingly explain clinical out-
come. The use of diffusion-weighted imaging in CG
patients has revealed white matter pathology that corre-
lated with (cognitive) outcome (Timmers et al., 2015).
The use of quantitative MR techniques may contribute to
the investigation of pathology in the normal appearing
white matter and grey matter, and therefore, quantitative
analysis of the MR images in this study will be
performed.
Conclusion
In this study, the deep- phenotyping of a representative
cohort of CG patients demonstrated a large variability in
clinical outcome. In our cohort, Gal-1-P levels did dis-
criminate between classical and NBS-detected variant
patients. However, both Gal-1-P and IgG N-glycans were
not associated with long-term complications. The variabil-
ity in clinical outcome necessitates individual and standar-
dized evaluation of all CG patients. Future studies to
increase knowledge and understanding of the pathophysi-
ology of CG and its long-term complications are needed
to determine the cause of the broad clinical outcome
spectrum in CG.
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